Phase I study finished

We have completed phase I study with JAK kinase inhibitors.

The JAK family of non-receptor tyrosine kinases regulates the transduction of signals from cytokines and their receptors by activating STAT transcription factors and modulating the expression of STAT-dependent genes. Excessive activation of the JAK/STAT pathway has been confirmed in immune-related diseases, where JAK kinases participate in the induction and maintenance of inflammation. The development of therapy based on the inhibition of JAK family kinases has applications in many areas: oncology by inhibiting excessive cell growth and proliferation (e.g. JAK2 inhibitor in myeloproliferative syndromes and leukemias), in immunology by regulating the secretion of pro-inflammatory cytokines (e.g. JAK1 inhibitor in chronic lung diseases inflammatory) and in transplantology due to its immunosuppressive effect (inhibition of JAK3 kinase). 

The study was performed with healthy volunteers in two parts: A (single ascending dose) and B (multiple ascending dose), with different doses and placebo control.

Go back

News

Completion of a single-center phase I study of the safety and pharmacokinetics of CPL207280

We have just completed a phase I study of safety and pharmacokinetics (part B) of an innovative therapy that could be used...

Read more …

GcLP quality certificate for laboratory procedures

The BRG Clinical Site received the GcLP quality certificate for laboratory procedures and is in the process of obtaining GMP certification for pharmaceutical procedures.

Read more …

Study for healthy people with a drug against Covid-19

In BRG we are currently performing a study for healthy people with a drug against Covid-19 .
In the project we are comparing experimental injectable drug called...

Read more …

Phase I study finished

Our site has just succesfully finished clinical stage of phase I (two parts) study with JAK kinase inhibitors.

Read more …

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

In BRG we are just starting Study for Healthy People with an Immune Drug - Part B. The aim of the following clinical trial...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲